Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.

Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.

uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.

uniQure N.V. experienced a significant stock decline of over 35% on September 29, 2026, following the release of updated 48-month data for AMT-130, its investigational gene therapy for Huntington's disease. The disappointing results have prompted a securities investigation by Kehoe Law Firm on behalf of affected investors.

Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.

uniQure N.V. announced the pricing of an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, generating approximately $225 million in gross proceeds. The offering is expected to close on June 25, 2026. The company is advancing gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe conditions.

Numero AI has acquired Royu in an undisclosed cash-and-stock transaction to combine AI-first fintech capabilities for enterprise finance operations. The merger brings together Royu's engineering expertise with Numero's finance domain knowledge to expand agentic AI systems across accounting close, reconciliation, reporting, order-to-cash, and technical accounting workflows. Royu co-founders Viswajith and Sathya will join Numero's leadership as Chief Product Officer and Chief Technology Officer respectively.

The Schall Law Firm is seeking investors who purchased uniQure N.V. securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resulting in investor losses.

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorting comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorted comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

uniQure N.V. faces a securities fraud class action lawsuit after the FDA rejected the company's data for its lead drug candidate AMT-130, causing a 49% stock price decline from $67.69 to $34.29 on November 3, 2025. Investors who purchased shares between September 24 and October 31, 2025 can file lead plaintiff applications by April 13, 2026.

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, NuScale Power Corporation, and uniQure N.V. The AMC lawsuit concerns alleged securities fraud related to APE (Preferred Equity Units) holders being excluded from a special dividend due to a technical loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.